METTL14 depletion was also shown not only to enhance cell resistance to highly active agents used in the treatment of advanced breast cancer (i.e., paclitaxel and doxorubicin) but also to confer radioprotective effects on ALDH+ breast cancer stem cells [48]. Here, METTL14 is linked to breast carcinoma.